Panacea Life Sciences Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Panacea Life Sciences Holdings, Inc. (PLSH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 205.00 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-04-01
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 0.00 shares.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 0.00 shares.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 3.50M shares, a 250.00% increase year-over-year.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 205.00K shares.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 1.00M shares, a 78.96% decline from fiscal 2019.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 4.75M shares, a 395.49% increase from fiscal 2018.
- Panacea Life Sciences Holdings, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 959.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | 0.00 shares derived: sum of 2 quarters · filed 2024-04-01 | 205.00K shares 10-K · filed 2024-04-01 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 205.00K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 205.00K shares 10-Q · filed 2023-08-15 | |||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2021-08-23 | 3.50M shares 10-Q · filed 2021-08-23 | 3.50M shares derived: sum of 3 quarters · filed 2021-08-23 | 3.50M shares derived: sum of 4 quarters · filed 2021-08-23 |
| 2021-03-31 | 3.50M shares 10-Q/A · filed 2021-05-27 | 3.50M shares derived: sum of 2 quarters · filed 2021-05-27 | 3.50M shares derived: sum of 3 quarters · filed 2021-05-27 | 3.50M shares derived: sum of 4 quarters · filed 2021-05-27 |
| 2020-12-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-23 | 0.00 shares derived: sum of 2 quarters · filed 2021-04-23 | 0.00 shares derived: sum of 3 quarters · filed 2021-04-23 | 1.00M shares 10-K/A · filed 2021-04-23 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-18 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-18 | 1.00M shares 10-Q · filed 2020-11-18 | 1.03M shares derived: sum of 4 quarters · filed 2021-04-23 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-19 | 1.00M shares 10-Q · filed 2020-08-19 | 1.03M shares derived: sum of 3 quarters · filed 2021-04-23 | -1.67M shares derived: sum of 4 quarters · filed 2021-04-23 |
| 2020-03-31 | 1.00M shares 10-Q · filed 2020-06-29 | 1.03M shares derived: sum of 2 quarters · filed 2021-04-23 | -1.67M shares derived: sum of 3 quarters · filed 2021-04-23 | 1.28M shares derived: sum of 4 quarters · filed 2021-04-23 |
| 2019-12-31 | 28.57K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-23 | -2.67M shares derived: sum of 2 quarters · filed 2021-04-23 | 278.57K shares derived: sum of 3 quarters · filed 2021-04-23 | 4.75M shares 10-K/A · filed 2021-04-23 |
| 2019-09-30 | -2.70M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 250.00K shares derived: sum of 2 quarters · filed 2019-11-14 | 4.72M shares 10-Q · filed 2019-11-14 | 4.01M shares derived: sum of 4 quarters · filed 2020-05-22 |
| 2019-06-30 | 2.95M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | 7.42M shares 10-Q · filed 2019-08-14 | 6.71M shares derived: sum of 3 quarters · filed 2020-05-22 | |
| 2019-03-31 | 4.47M shares 10-Q · filed 2019-05-20 | 3.76M shares derived: sum of 2 quarters · filed 2020-05-22 | ||
| 2018-12-31 | -715.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-22 | 959.38K shares 10-K · filed 2020-05-22 | ||
| 2018-09-30 | 1.68M shares 10-Q · filed 2018-11-14 |